Cerus (CERS) Asset Writedowns and Impairment (2022 - 2023)
Cerus' (CERS) quarterly Asset Writedowns and Impairment came in at $1.5 million in Q3 2023, up 375.46% quarter-over-quarter from -$542000.0 in Q4 2022.
Cerus (CERS) Asset Writedowns and Impairment (2022 - 2023) Analysis & Trends
Cerus has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting $1.5 million for Q3 2023.
- Asset Writedowns and Impairment for Q3 2023 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $951000.0 (changed N/A YoY), and the FY2023 annual result was $1.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment came in at $1.5 million for Q3 2023 at Cerus, up from -$542000.0 in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.5 million in Q3 2023 to a low of -$542000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Cerus | 496.03 Mn | 416.34 Mn | 27.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 1.49 Mn |
| Sep 30, 2023 | 1.49 Mn |
| Dec 31, 2022 | -542,000.00 |
| Dec 31, 2022 | -542,000.00 |
| Mar 31, 2022 | 542,000.00 |
| Mar 31, 2022 | 542,000.00 |